Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Weiming Li, Yanli Zhang, Huanling Zhu, Yunfan Yang, Na Xu, Bingcheng Liu, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu
Institutions: Wuhan Union Hospital, Huazhong University of Science and Technology, Zhengzhou University, Sichuan University, West China Hospital of Sichuan University, Nanfang Hospital, Southern Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Ascentage Pharma Group Inc. (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162541382
Cites:
Cited by:
Related to: